论文信息 - A phase Ib dose escalation study of the OX40 agonist MOXR0916 and the PD-L1 inhibitor atezolizumab in patients with advanced solid tumors. - 字舞流文

A phase Ib dose escalation study of the OX40 agonist MOXR0916 and the PD-L1 inhibitor atezolizumab in patients with advanced solid tumors.

L. Chow | J. Infante | L. Siu | G. McArthur | M. Pishvaian | H. Gilbert | A. Hansen | M. Gordon | Stephen V. Liu | S. Sandhu | T. Bauer | J. Kim | Chi-Chung Li | E. Stefanich | I. Rhee | B. McCall | F. Tsai | Maria Anderson | M. Huseni